Armistice Capital’s GeneDx Holdings WGS Stock Holding History

Armistice Capital’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,216	Closed	-$288K	–	444
2025 Q4	$288K	Buy	+2,216	New	+$304K	﹤0.01%	299

Other funds holding WGS

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ZDA

Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital's WGS Position: Q1 2026 in Review

Armistice Capital sold out of GeneDx Holdings (WGS) in Q1 2026, closing a stake of 2,216 shares — an estimated $288K sold.

Armistice Capital first reported a position in WGS in Q4 2025 and held it in 1 quarter. The position peaked at $288K in Q4 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

Armistice Capital reported no remaining GeneDx Holdings position as of Q1 2026 after selling out during the quarter.
Armistice Capital sold 2,216 GeneDx Holdings shares in Q1 2026, an estimated $288K.
Armistice Capital first reported a position in GeneDx Holdings in Q4 2025 and held it in 1 quarter.
Armistice Capital's GeneDx Holdings position peaked at $288K in Q4 2025.
240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.